Jump to content


E-Newsletter Signup Like us on Facebook Sign Up For Our e-Newsletter
Photo

Amicus Therapeutics Enters Collaboration With Biogen Idec for PD


  • Please log in to reply
No replies to this topic

#1 Kathrynne Holden, MS

Kathrynne Holden, MS

    Moderator

  • Ask the Dietician Moderators
  • PipPipPip
  • 3,045 posts
  • Locationfacebook.com/Parkinsons.Chew.On.This.

Posted 20 September 2013 - 07:39 PM

Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
 

Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease

Biogen Idec to Fund 100% of Discovery, Development, and Commercialization Costs

CRANBURY, N.J., Sept. 10, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has entered a collaboration with Biogen Idec (Nasdaq:BIIB) to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease. The collaboration will build upon preclinical studies at Amicus and independent published research that suggest increasing activity of the lysosomal enzyme glucocerobrosidase (GCase) in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson's disease.

 

http://online.wsj.co...910-904316.html


Best regards,

Kathrynne Holden, MS

--

For a Parkinson Tip of the Day visit:

<!-- m -->http://www.nutritionucanlivewith.com/<!-- m -->




0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users